Lannett Co (LCI) Beats Expectations Without Levothyroxine - BMO Capital

August 28, 2019 7:59 AM EDT Send to a Friend
BMO Capital analyst Gary Nachman reiterated a Market Perform rating and $10.00 price target on Lannett Co (NYSE: LCI) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login